医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cross Protection by Encephalitis Vaccine as a Factor for Lesser COVID Mortality in Some Regions

2020年04月23日 PM08:34
このエントリーをはてなブックマークに追加


 

TOKYO

A significant discrepancy in mortality among even geographically close regions could be explained by a cross protection induced by Japanese Encephalitis Vaccine (JEV) and/or Tick-Borne Encephalitis Vaccine (TEV) according to Dr Shojiro Katoh, President, Edogawa Hospital. He along with his international team of researchers of Edogawa Evolutionary Lab of Science (EELS), have published their opinion in Archives of Academic Emergency Medicine, a peer reviewed journal (http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/683).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200423005409/en/

Edogawa Hospital, Tokyo, Japan, whose physicians have hypothesized on cross protection to COVID-19 by Encephalitis vaccine (Photo: Business Wire)

Edogawa Hospital, Tokyo, Japan, whose physicians have hypothesized on cross protection to COVID-19 by Encephalitis vaccine (Photo: Business Wire)

The COVID-19 pandemic with 2,478,634 people infected, and 170,000 deaths globally, has caused unprecedented implications on day-to-day life and the global economy. Loss of lives in Spain (20,852) and Italy (24,114) are more than China (4,632), the epicenter of the outbreak, where JEV and/or TEV is included in national immunization schedule, like Japan (186) and Austria (463). In China, the mortality is 2.3% compared to 7.3% in Italy and 10.41% in Spain, where JEV and/or TEV is not routine. JEV immunization is widespread, or in the national vaccination programs of Japan, Laos, Malaysia, Nepal, South Korea, Thailand, Sri Lanka, and Vietnam where the mortality rate is relatively lower than countries that don’t. Going by the above data, cross-protection conferred by the encephalitis vaccine(s) could be thought as a reason for lower mortality, which must be proven by necessary validations. If any such cross protection could be confirmed to be of help even at least for a specific group, especially the vulnerable population such as the elderly and those with co-morbid conditions, may pave way for arriving at efficient strategies for tackling COVID-19.

“As we are not sure when a drug or vaccine will be available to relieve humankind from the clutches of this pandemic, our modest contribution through this hypothesis, we do hope may trigger similar or better thoughtful ideas,” said Dr. Katoh, whose inter-disciplinary team of clinicians and scientists are working on biomaterials based in vitro viral replication cum drug discovery platforms (https://www.ncbi.nlm.nih.gov/pubmed/26470963), food supplements to enhance immunity and wellness (https://pubmed.ncbi.nlm.nih.gov/24409973/) and autologous Natural Killer cells (NK cells) based immunotherapy for cancer (https://pubmed.ncbi.nlm.nih.gov/28894585/). Their Biomaterial lab jointly with JBM Inc is working on cell culture and tissue engineering in regenerative medicine, beside novel drug development systems and methodologies for tackling both cancer and viruses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200423005409/en/

CONTACT

For queries contact:

Samuel JK Abraham

GN Corporation

info@gncorporation.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • MetLife’s 360Health Wins Gold Stevie®
  • PHC株式会社:配薬支援および決済サービスを実現した「ヘルスケア手帳」サービスを導入-患者さんへの医療サービス向上を目指したクラウドサービス連携ソリューション「Medicom Cloudコネクト」第一弾
  • iProov Partners with IDV Pacific to Enhance Online Identity Verification in Australia and New Zealand
  • MedTech Innovator Selects 20 Startups for Annual Asia Pacific Accelerator and Announces Extended Asia Pacific Partnership With Johnson & Johnson
  • IGC Reports Financial Results for the Fiscal Year Ended March 31, 2020